---
title: "Citius Pharmaceuticals Raises ~$5M; Issues Warrants in Registered Direct and Private Placement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284054908.md"
description: "Citius Pharmaceuticals raised approximately $5 million through a registered direct offering and private placement with institutional investors. The deal included 4,730,457 common shares at $0.985, pre-funded warrants for 345,686 shares, and 5,076,143 common warrants exercisable at $0.86. Net proceeds of about $4.5 million will be used for LYMPHIR commercialization and development. H.C. Wainwright acted as the exclusive placement agent, receiving a 7% fee and warrants for 355,330 shares."
datetime: "2026-04-24T21:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284054908.md)
  - [en](https://longbridge.com/en/news/284054908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284054908.md)
---

# Citius Pharmaceuticals Raises ~$5M; Issues Warrants in Registered Direct and Private Placement

Citius Pharmaceuticals raised approximately $5.0 million through a registered direct offering and concurrent private placement with institutional investors. The transaction included 4,730,457 common shares at $0.985, pre-funded warrants for 345,686 shares at $0.0001 exercise price, and 5,076,143 common warrants exercisable at $0.86 for five years. Net proceeds of about $4.5 million are earmarked for LYMPHIR commercialization, development initiatives, and general corporate purposes. H.C. Wainwright and Co. served as exclusive placement agent, receiving a 7.0% fee, expense reimbursements, and five-year placement agent warrants for 355,330 shares at a $1.2313 exercise price.

**Agreement 1: Citius Pharmaceuticals Raises ~$5M in Registered Direct Offering and Private Placement**

-   **Agreement type**: Securities purchase agreement for registered direct offering and concurrent private placement
-   **Counterparty**: Institutional investors
-   **Signed / Effective**: Apr 23 2026 / same
-   **Reason**: Raise capital for commercialization and development

**Agreement 2: Citius Pharmaceuticals Grants Placement Agent Warrants to Wainwright in $5M Financing**

-   **Agreement type**: Exclusive placement agent engagement and placement agent warrants
-   **Counterparty**: H.C. Wainwright and Co.
-   **Signed / Effective**: Apr 23 2026 / same
-   **Duration / Termination**: 5 years
-   **Reason**: Facilitate and compensate for the financing

Original SEC Filing: Citius Pharmaceuticals, Inc. \[ CTXR \] - 8-K - Apr. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CTXR.US](https://longbridge.com/en/quote/CTXR.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC](https://longbridge.com/en/news/287274216.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)